Literature DB >> 19159884

Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans.

Kyung Eun Yun1, Chan Yim Shin, Yeong Sook Yoon, Hye Soon Park.   

Abstract

OBJECTIVE: Metabolic syndrome is associated with increased cardiovascular morbidity and mortality. Nonalcoholic fatty liver disease (NAFLD) is closely associated with metabolic syndrome. This study investigated the relationship between elevated alanine aminotransferase (ALT) levels, as a proxy marker of NAFLD, and death from cardiovascular disease (CVD) or diabetes in a Korean population.
METHODS: The study population consisted of 37,085 patients who underwent health examinations at the Health Promotion Center of the Asan Medical Center, Seoul, Korea, in 2000 and 2001. Individuals with viral hepatitis or alcoholic liver disease were excluded from the study. The relationship between baseline ALT levels and CVD- or diabetes-related mortality was determined for a median period of 5.0 years.
RESULTS: A total of 407 deaths occurred during the follow-up period, with 91 deaths resulting from CVD or diabetes. The multivariate relative risk (RR) and 95% confidence interval (CI) for CVD- or diabetes-related mortality in patients with ALT levels >40IU/L were 2.26 (1.22-4.19). The multivariate RR and 95% CI for CVD- or diabetes-related mortality in patients with the highest quartile of ALT levels (> or =31IU/L) were 2.28 (95% CI: 1.02-5.08) when the lowest quartile (< or =15IU/L) was used as a reference.
CONCLUSION: Our findings demonstrate that elevated ALT levels are independently associated with increased CVD- or diabetes-related mortality in Koreans. Thus, elevated ALT levels, as a marker for NAFLD, may serve as a surrogate predictor of CVD- or diabetes-related mortality among the Korean population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19159884     DOI: 10.1016/j.atherosclerosis.2008.12.012

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  38 in total

Review 1.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

2.  The association of low serum alanine aminotransferase activity with mortality in the US population.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Am J Epidemiol       Date:  2013-09-26       Impact factor: 4.897

Review 3.  Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.

Authors:  Rajesh Parsanathan; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2019-10-16       Impact factor: 1.894

Review 4.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

5.  Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysis.

Authors:  Lavanya Ravichandran; Shaun G Goodman; Andrew T Yan; Aurora Mendelsohn; Joel G Ray
Journal:  Heart Asia       Date:  2012-10-12

Review 6.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

7.  Combination drug treatment in patients with non-alcoholic fatty liver disease.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Hepatol       Date:  2010-04-27

Review 8.  Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

Authors:  Michael S Kostapanos; Anastazia Kei; Moses S Elisaf
Journal:  World J Hepatol       Date:  2013-09-27

Review 9.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

10.  Hepatic steatosis in overweight/obese females: new screening method for those at risk.

Authors:  Giovanni Tarantino; Genoveffa Pizza; Annamaria Colao; Fabrizio Pasanisi; Paolo Conca; Patrizia Colicchio; Carmine Finelli; Franco Contaldo; Carolina Di Somma; Silvia Savastano
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.